Navigation Links
The Olive Branch Fund Announces Funding Award to Harvard Researcher
Date:6/29/2011

NASHVILLE, Tenn., June 29, 2011 /PRNewswire-USNewswire/ -- The Olive Branch Fund: A Thisbe and Noah Scott Legacy, an organization dedicated to combating pediatric motor neuron diseases, today announced its first funding award to Kevin Eggan, Ph.D., Associate Professor of Stem Cell and Regenerative Biology at Harvard University.  The award will support Dr. Eggan's ongoing research investigating the neuromuscular system and the diseases that affect it.  Dr. Eggan is a leading researcher in motor neuron disease. He received the MacArthur Fellowship in 2006 and received the Presidential Early Career Award for Science and Engineering from President George Bush in 2008.

"This initial grant to Dr. Eggan is an incredibly exciting milestone for us as we begin to invest the funds we have raised to support the mission of The Olive Branch Fund and to advance groundbreaking research in the fight against motor neuron disease.  We are pleased this award will support Dr. Eggan's important research while also providing clues into the mechanisms of Brown-Vialetto-Van Laere syndrome," said Laurian Scott, Co-Founder of The Olive Branch Fund.  Brown-Vialetto-Van Laere syndrome is a rare, progressive, neurodegenerative motor neuron disorder that specifically includes palsies (paralysis) of the cranial nerves, and is sometimes referred to as "bulbar palsy."  Throughout the past century, few cases of Brown-Vialetto-Van Laere have been reported in the literature, but those numbers are growing.

The Olive Branch Fund: A Thisbe and Noah Scott Legacy was formed in 2008 to promote research, awareness, and support for families of all pediatric motor neuron diseases in memory of Laurian and John Scott's two children, Noah, who passed away at 19 months, and Thisbe, who passed away just before her third birthday.  Six cities nationwide, including Nashville, Memphis, Richmond, and Phoenix, have held fundraisers for The Olive Branch Fund, raising over $500,000.  These fundraisers are titled "A Mighty Voice" and aid The Olive Branch Fund in carrying out its mission worldwide.

The Olive Branch Fund: A Thisbe and Noah Scott Legacy is a component fund of the Community Foundation of Middle Tennessee.  For more information, please visit www.theolivebranchfund.org.


'/>"/>
SOURCE The Olive Branch Fund
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New antioxidant compounds have been identified in foods such as olive oil, honey and nuts
2. New antioxidant compounds have been identified in foods such as olive oil, honey and nuts
3. Powered by olive stones? Turning waste stones into fuel
4. Rcadia COR Analyzer System Safely Rules Out Coronary Artery Disease in Main Coronary Arteries and Branch Vessels
5. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
6. Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ
7. Stunning Attendance for ChemOutsourcing Show on September 8-9 in Long Branch, NJ
8. Verenium Announces Signing of Lease for New Office and Lab Space
9. Celladon Corporation Announces Publication of Advanced Heart Failure Clinical Trial Results With MYDICAR® Enzyme Replacement Therapy in the Journal Circulation
10. Scotland Announces Goal to Double Life Sciences Contribution to Scottish Economy by 2020 at BIO
11. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
(Date:12/8/2016)... Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: ... develops and plans to commercialize innovative therapeutics for ... common stock were approved for trading on the ... on the OTCQX, effective today, under the ticker ... OTCQX market, companies must meet high financial standards, ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selector™ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
Breaking Biology Technology:
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/5/2016)... -- The Office of Justice Programs, National Institute of ... or Replace Medico Legal Autopsies?" on NIJ.gov.  The ... forensic autopsies with postmortem X-ray computed tomography, commonly ... to recommendations made by The National Academy of ... a potential component of medicolegal death investigations. NIJ,s ...
Breaking Biology News(10 mins):